1254831-48-5

Basic information

• Product Name: 3-(6-tert-butoxycarbonylamino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester
• Synonyms: 3-(6-tert-butoxycarbonylamino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester
• CAS NO: 1254831-48-5
• Molecular Weight: 442.558
• Mol File: 1254831-48-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(6-tert-butoxycarbonylamino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(6-tert-butoxycarbonylamino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester(1254831-48-5)
• EPA Substance Registry System: 3-(6-tert-butoxycarbonylamino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester(1254831-48-5)

Safety Data

• Hazardous Substances Data: 1254831-48-5(Hazardous Substances Data)

Upstream product

• 1254831-47-4 (1-cyclohexyl-1H-imidazol-4-yl)-acetic acid ethyl ester 
• 1254831-46-3 (E)-2-(1-cyclohexyl-1H-imidazol-4-yl)-3-hydroxy-but-2-enedioic acid diethyl ester 
• 304873-96-9 (5-bromomethyl-pyridin-2-yl)-carbamic acid tert-butyl ester 

Downstream Products

• 1438404-18-2 (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid sodium salt 
• 1437501-98-8 (R)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester 
• 1438404-22-8 (S)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester 
• 1375150-73-4 (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid 
• 1437501-99-9 (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid ethyl ester naphthalene-1,5-disulfonic acid salt 

Relevant articles and documents

CRYSTALLINE SALTS OF R)-3-[6-AMINO-PYRIDIN-3-YL]-2-(1-CYCLOHEXYL-1H-IMIDAZOL-4-YL)-PROPIONIC ACID

The invention relates to a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1 -cyclohexyl- 1 H-imidazol-4-yl)-propionic acid which is in a crystalline form or in at least partially crystalline form as a monohydrate or anhydrate, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor).

PROCESS FOR THE PREPARATION OF A COMPOUND USEFUL AS AN INHIBITOR OF TAFIA

The present invention relates to a process for the preparation of a compound of the formula (I), which comprises reacting a compound of the formula (IV) with an oxalic acid diester and to novel intermediate compounds used therein.